Zc3h13/Flacc Is Required for Adenosine Methylation by Bridging the Mrna- Binding Factor Rbm15/Spenito to the M6a Machinery Component Wtap/Fl(2)D
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Xio Is a Component of the Drosophila Sex Determination Pathway and RNA N6-Methyladenosine Methyltransferase Complex
Xio is a component of the Drosophila sex determination pathway and RNA N6-methyladenosine methyltransferase complex Jian Guoa,b, Hong-Wen Tangc, Jing Lia,b, Norbert Perrimonc,d,1, and Dong Yana,1 aKey Laboratory of Insect Developmental and Evolutionary Biology, Chinese Academy of Sciences Center for Excellence in Molecular Plant Sciences, Shanghai Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, 200032 Shanghai, China; bUniversity of Chinese Academy of Sciences, 100049 Beijing, China; cDepartment of Genetics, Harvard Medical School, Boston, MA 02115; and dHoward Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 Contributed by Norbert Perrimon, February 14, 2018 (sent for review December 6, 2017; reviewed by James W. Erickson and Helen Salz) N6-methyladenosine (m6A), the most abundant chemical modifica- reader YT521-B, are required for Drosophila sex determination 6 tion in eukaryotic mRNA, has been implicated in Drosophila sex and Sxl splicing regulation. Further, m A modification sites have determination by modifying Sex-lethal (Sxl) pre-mRNA and facili- been mapped to Sxl introns, thus facilitating Sxl pre-mRNA al- 6 tating its alternative splicing. Here, we identify a sex determina- ternative splicing. Importantly, m A methylation is required in CG7358 xio human dosage compensation by modifying the long noncoding tion gene, , and rename it according to its loss-of- 6 function female-to-male transformation phenotype. xio encodes RNA XIST,suggestingthatmA-mediated gene regulation is an ancient -
N6-Methyladenosine Role in Acute Myeloid Leukaemia
International Journal of Molecular Sciences Review N6-Methyladenosine Role in Acute Myeloid Leukaemia Zaira Ianniello and Alessandro Fatica * ID Department of Biology and Biotechnology “Charles Darwin”, Sapienza University of Rome, 00185 Rome, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-06-4991-2341 Received: 30 July 2018; Accepted: 8 August 2018; Published: 9 August 2018 Abstract: We are currently assisting in the explosion of epitranscriptomics, which studies the functional role of chemical modifications into RNA molecules. Among more than 100 RNA modifications, the N6-methyladenosine (m6A), in particular, has attracted the interest of researchers all around the world. m6A is the most abundant internal chemical modification in mRNA, and it can control any aspect of mRNA post-transcriptional regulation. m6A is installed by “writers”, removed by “erasers”, and recognized by “readers”; thus, it can be compared to the reversible and dynamic epigenetic modifications in histones and DNA. Given its fundamental role in determining the way mRNAs are expressed, it comes as no surprise that alterations to m6A modifications have a deep impact in cell differentiation, normal development and human diseases. Here, we review the proteins involved in m6A modification in mammals, m6A role in gene expression and its contribution to cancer development. In particular, we will focus on acute myeloid leukaemia (AML), which provides an initial indication of how alteration in m6A modification can disrupt normal cellular differentiation and lead to cancer. Keywords: m6A; RNA; AML; leukaemia; epitranscriptomics 1. Introduction Leukaemogenesis is caused by gene mutations and chromosomal aberrations resulting in changes of gene expression and, eventually, alteration of cell growth/differentiation programs [1]. -
Mutational Landscape Differences Between Young-Onset and Older-Onset Breast Cancer Patients Nicole E
Mealey et al. BMC Cancer (2020) 20:212 https://doi.org/10.1186/s12885-020-6684-z RESEARCH ARTICLE Open Access Mutational landscape differences between young-onset and older-onset breast cancer patients Nicole E. Mealey1 , Dylan E. O’Sullivan2 , Joy Pader3 , Yibing Ruan3 , Edwin Wang4 , May Lynn Quan1,5,6 and Darren R. Brenner1,3,5* Abstract Background: The incidence of breast cancer among young women (aged ≤40 years) has increased in North America and Europe. Fewer than 10% of cases among young women are attributable to inherited BRCA1 or BRCA2 mutations, suggesting an important role for somatic mutations. This study investigated genomic differences between young- and older-onset breast tumours. Methods: In this study we characterized the mutational landscape of 89 young-onset breast tumours (≤40 years) and examined differences with 949 older-onset tumours (> 40 years) using data from The Cancer Genome Atlas. We examined mutated genes, mutational load, and types of mutations. We used complementary R packages “deconstructSigs” and “SomaticSignatures” to extract mutational signatures. A recursively partitioned mixture model was used to identify whether combinations of mutational signatures were related to age of onset. Results: Older patients had a higher proportion of mutations in PIK3CA, CDH1, and MAP3K1 genes, while young- onset patients had a higher proportion of mutations in GATA3 and CTNNB1. Mutational load was lower for young- onset tumours, and a higher proportion of these mutations were C > A mutations, but a lower proportion were C > T mutations compared to older-onset tumours. The most common mutational signatures identified in both age groups were signatures 1 and 3 from the COSMIC database. -
Identifying the Role of Wilms Tumor 1 Associated Protein in Cancer Prediction Using Integrative Genomic Analyses
MOLECULAR MEDICINE REPORTS 14: 2823-2831, 2016 Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses LI‑SHENG WU1*, JIA-YI QIAN2*, MINGHAI WANG3* and HAIWEI YANG4 1Department of General Surgery, Anhui Provincial Hospital, Anhui Medical University, Hefei, Anhui 230001; 2Department of Breast Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029; 3Department of General Surgery, The First Affiliated Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241002; 4Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China Received August 31, 2015; Accepted June 2, 2016 DOI: 10.3892/mmr.2016.5528 Abstract. The Wilms tumor suppressor, WT1 was first iden- regulatory factor 1, glucocorticoid receptor and peroxisome tified due to its essential role in the normal development of proliferator‑activated receptor γ transcription factor binding the human genitourinary system. Wilms tumor 1 associated sites were identified in the upstream (promoter) region of the protein (WTAP) was subsequently revealed to interact with human WTAP gene, suggesting that these transcription factors WT1 using yeast two‑hybrid screening. The present study may be involved in WTAP functions in tumor formation. identified 44 complete WTAP genes in the genomes of verte- brates, including fish, amphibians, birds and mammals. The Introduction vertebrate WTAP proteins clustered into the primate, rodent and teleost lineages using phylogenetic tree analysis. From The Wilms tumor suppressor gene WT1 was first identified 1,347 available SNPs in the human WTAP gene, 19 were due to its essential role in the normal development of the identified to cause missense mutations. -
WTAP Mouse Monoclonal Antibody [Clone ID: OTI12G7] Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA808317 WTAP Mouse Monoclonal Antibody [Clone ID: OTI12G7] Product data: Product Type: Primary Antibodies Clone Name: OTI12G7 Applications: IHC, WB Recommended Dilution: WB 1:2000, IHC 1:150 Reactivity: Human, Mouse, Rat Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Human recombinant protein fragment corresponding to amino acids 2-106 of human WTAP(NP_004897) produced in E.coli. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 44.1 kDa Gene Name: Wilms tumor 1 associated protein Database Link: NP_004897 Entrez Gene 60532 MouseEntrez Gene 499020 RatEntrez Gene 9589 Human Q15007 Background: The Wilms tumor suppressor gene WT1 appears to play a role in both transcriptional and posttranscriptional regulation of certain cellular genes. This gene encodes a WT1-associating protein, which is a ubiquitously expressed nuclear protein. Like WT1 protein, this protein is localized throughout the nucleoplasm as well as in speckles and partially colocalizes with splicing factors. Alternative splicing of this gene results in several transcript variants encoding three different isoforms. [provided by RefSeq, Jul 2012] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. -
Aberrant Expression of Enzymes Regulating M6a Mrna Methylation: Implication in Cancer
Cancer Biol Med 2018. doi: 10.20892/j.issn.2095-3941.2018.0365 REVIEW Aberrant expression of enzymes regulating m6A mRNA methylation: implication in cancer Natalia Pinello1,2, Stephanie Sun1,2, Justin Jong-Leong Wong1,2 1Epigenetics and RNA Biology Program Centenary Institute, The University of Sydney, Camperdown 2050, Australia; 2Sydney Medical School, The University of Sydney, Camperdown 2050, Australia ABSTRACT N6-methyladenosine (m6A) is an essential RNA modification that regulates key cellular processes, including stem cell renewal, cellular differentiation, and response to DNA damage. Unsurprisingly, aberrant m6A methylation has been implicated in the development and maintenance of diverse human cancers. Altered m6A levels affect RNA processing, mRNA degradation, and translation of mRNAs into proteins, thereby disrupting gene expression regulation and promoting tumorigenesis. Recent studies have reported that the abnormal expression of m6A regulatory enzymes affects m6A abundance and consequently dysregulates the expression of tumor suppressor genes and oncogenes, including MYC, SOCS2, ADAM19, and PTEN. In this review, we discuss the specific roles of m6A “writers", “erasers”, and “readers” in normal physiology and how their altered expression promotes tumorigenesis. We also describe the potential of exploiting the aberrant expression of these enzymes for cancer diagnosis, prognosis, and the development of novel therapies. KEYWORDS RNA modification; N6-methyladenosine (m6A); cancer; tumor suppressor; oncogene Introduction mRNAs and their consequent transcriptional outcomes include RNA specific methylases (writers), demethylases RNA modifications have recently been shown to play (erasers), and reader proteins (Figure 1). important roles in normal and disease biology. Over 170 Together, the tightly-regulated functions of m6A writers, different types of post-transcriptional modifications have erasers, and readers are critical in maintaining the integrity of been identified in RNA, many of which have unknown m6A RNA modification in cells. -
Analysis of Diet-Induced Differential Methylation, Expression, And
www.nature.com/scientificreports OPEN Analysis of diet-induced diferential methylation, expression, and interactions of lncRNA and protein- Received: 2 March 2018 Accepted: 29 June 2018 coding genes in mouse liver Published: xx xx xxxx Jose P. Silva1 & Derek van Booven2 Long non-coding RNAs (lncRNAs) regulate expression of protein-coding genes in cis through chromatin modifcations including DNA methylation. Here we interrogated whether lncRNA genes may regulate transcription and methylation of their fanking or overlapping protein-coding genes in livers of mice exposed to a 12-week cholesterol-rich Western-style high fat diet (HFD) relative to a standard diet (STD). Deconvolution analysis of cell type-specifc marker gene expression suggested similar hepatic cell type composition in HFD and STD livers. RNA-seq and validation by nCounter technology revealed diferential expression of 14 lncRNA genes and 395 protein-coding genes enriched for functions in steroid/cholesterol synthesis, fatty acid metabolism, lipid localization, and circadian rhythm. While lncRNA and protein-coding genes were co-expressed in 53 lncRNA/protein-coding gene pairs, both were diferentially expressed only in 4 lncRNA/protein-coding gene pairs, none of which included protein- coding genes in overrepresented pathways. Furthermore, 5-methylcytosine DNA immunoprecipitation sequencing and targeted bisulfte sequencing revealed no diferential DNA methylation of genes in overrepresented pathways. These results suggest lncRNA/protein-coding gene interactions in cis play a minor role mediating hepatic expression of lipid metabolism/localization and circadian clock genes in response to chronic HFD feeding. More than 70% of the mammalian genome is transcribed as non-coding RNA (ncRNA) while only 1–2% of the mammalian genome is transcribed as protein-coding RNA1–3. -
RBM15 Modulates the Function of Chromatin Remodeling Factor BAF155 Through RNA Methylation in Developing Cortex
Molecular Neurobiology (2019) 56:7305–7320 https://doi.org/10.1007/s12035-019-1595-1 RBM15 Modulates the Function of Chromatin Remodeling Factor BAF155 Through RNA Methylation in Developing Cortex Yuanbin Xie1,2 & Ricardo Castro-Hernández1 & Godwin Sokpor1 & Linh Pham1 & Ramanathan Narayanan1,3 & Joachim Rosenbusch1 & Jochen F. Staiger1,2 & Tran Tuoc1,2 Received: 5 February 2019 /Accepted: 2 April 2019 /Published online: 24 April 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Chromatin remodeling factor BAF155 is an important regulator of many biological processes. As a core and scaffold subunit of the BAF (SWI/SNF-like) complex, BAF155 is capable of regulating the stability and function of the BAF complex. The spatiotemporal expression of BAF155 during embryogenesis is essential for various aspects of organogenesis, particularly in the brain development. However, our understanding of the mechanisms that regulate the expression and function of BAF155 is limited. Here, we report that RBM15, a subunit of the m6A methyltransferase complex, interacts with BAF155 mRNA and mediates BAF155 mRNA degradation through the mRNA methylation machinery. Ablation of endogenous RBM15 expression in cultured neuronal cells and in the developing cortex augmented the expression of BAF155. Conversely, RBM15 overexpres- sion decreased BAF155 mRNA and protein levels, and perturbed BAF155 functions in vivo, including repression of BAF155- dependent transcriptional activity and delamination of apical radial glial progenitors as a hallmark of basal radial glial progenitor genesis. Furthermore, we demonstrated that the regulation of BAF155 by RBM15 depends on the activity of the mRNA methylation complex core catalytic subunit METTL3. Altogether, our findings reveal a new regulatory avenue that elucidates how BAF complex subunit stoichiometry and functional modulation are achieved in mammalian cells. -
Oncoscore: a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes
www.nature.com/scientificreports OPEN OncoScore: a novel, Internet- based tool to assess the oncogenic potential of genes Received: 06 July 2016 Rocco Piazza1, Daniele Ramazzotti2, Roberta Spinelli1, Alessandra Pirola3, Luca De Sano4, Accepted: 15 March 2017 Pierangelo Ferrari3, Vera Magistroni1, Nicoletta Cordani1, Nitesh Sharma5 & Published: 07 April 2017 Carlo Gambacorti-Passerini1 The complicated, evolving landscape of cancer mutations poses a formidable challenge to identify cancer genes among the large lists of mutations typically generated in NGS experiments. The ability to prioritize these variants is therefore of paramount importance. To address this issue we developed OncoScore, a text-mining tool that ranks genes according to their association with cancer, based on available biomedical literature. Receiver operating characteristic curve and the area under the curve (AUC) metrics on manually curated datasets confirmed the excellent discriminating capability of OncoScore (OncoScore cut-off threshold = 21.09; AUC = 90.3%, 95% CI: 88.1–92.5%), indicating that OncoScore provides useful results in cases where an efficient prioritization of cancer-associated genes is needed. The huge amount of data emerging from NGS projects is bringing a revolution in molecular medicine, leading to the discovery of a large number of new somatic alterations that are associated with the onset and/or progression of cancer. However, researchers are facing a formidable challenge in prioritizing cancer genes among the variants generated by NGS experiments. Despite the development of a significant number of tools devoted to cancer driver prediction, limited effort has been dedicated to tools able to generate a gene-centered Oncogenic Score based on the evidence already available in the scientific literature. -
Anti-RBM15 Antibody (ARG43273)
Product datasheet [email protected] ARG43273 Package: 100 μl anti-RBM15 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes RBM15 Tested Reactivity Hu Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name RBM15 Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 530-780 of Human RBM15 (NP_001188474.1). Conjugation Un-conjugated Alternate Names Putative RNA-binding protein 15; RNA-binding motif protein 15; OTT1; One-twenty two protein 1; SPEN; OTT Application Instructions Application table Application Dilution IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control HL-60 Calculated Mw 107 kDa Observed Size ~ 115 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/3 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol RBM15 Gene Full Name RNA binding motif protein 15 Background Members -
Cytogenetic and Molecular Characterization of the Macro- And
University of Ulm Department of Human Genetics Prof. Dr. med. Walther Vogel Cytogenetic and Molecular Characterization of the Macro- and Micro-inversions, which Distinguish the Human and the Chimpanzee Karyotypes - from Speciation to Polymorphism Thesis Applying for the Degree of Doctor of Human Biology (Dr. hum. biol.) Faculty of Medicine University of Ulm Presented by Justyna Monika Szamalek from Wrze śnia in Poland 2006 Amtierender Dekan: Prof. Dr. Klaus-Michael Debatin 1. Berichterstatter: Prof. Dr. med. Horst Hameister 2. Berichterstatter: Prof. Dr. med. Konstanze Döhner Tag der Promotion: 28.07.2006 Content Content 1. Introduction ...................................................................................................................7 1.1. Primate phylogeny........................................................................................................7 1.2. Africa as the place of human origin and the living area of the present-day chimpanzee populations .................................................................9 1.3. Cytogenetic and molecular differences between human and chimpanzee genomes.............................................................................................10 1.4. Cytogenetic and molecular differences between common chimpanzee and bonobo genomes................................................................................17 1.5. Theory of speciation .....................................................................................................18 1.6. Theory of selection -
Local Protein Translation and RNA Processing of Synaptic Proteins in Autism Spectrum Disorder
International Journal of Molecular Sciences Review Local Protein Translation and RNA Processing of Synaptic Proteins in Autism Spectrum Disorder Yuyoung Joo * and David R. Benavides Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-410-706-5799 Abstract: Autism spectrum disorder (ASD) is a heritable neurodevelopmental condition associated with impairments in social interaction, communication and repetitive behaviors. While the under- lying disease mechanisms remain to be fully elucidated, dysfunction of neuronal plasticity and local translation control have emerged as key points of interest. Translation of mRNAs for critical synaptic proteins are negatively regulated by Fragile X mental retardation protein (FMRP), which is lost in the most common single-gene disorder associated with ASD. Numerous studies have shown that mRNA transport, RNA metabolism, and translation of synaptic proteins are important for neuronal health, synaptic plasticity, and learning and memory. Accordingly, dysfunction of these mechanisms may contribute to the abnormal brain function observed in individuals with autism spectrum disorder (ASD). In this review, we summarize recent studies about local translation and mRNA processing of synaptic proteins and discuss how perturbations of these processes may be related to the pathophysiology of ASD. Keywords: local translation; RNA processing; RNA binding protein; synaptic protein; neuronal plasticity; autism Citation: Joo, Y.; Benavides, D.R. Local Protein Translation and RNA Processing of Synaptic Proteins in Autism Spectrum Disorder. Int. J. Mol. 1. Introduction Sci. 2021, 22, 2811. https://doi.org/ Autism spectrum disorder (ASD) represents a group of neurodevelopmental disorders 10.3390/ijms22062811 characterized by impairments in communication and social behavior.